Open label, multicenter study to evaluate safety/tolerability and efficacy of deferasirox (ICL670) in myelodysplastic syndrome patients with chronic transfusional haemosiderosis.
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2016
At a glance
- Drugs Deferasirox (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 24 Nov 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 24 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.